TY - JOUR
T1 - Mass Spectrometry-based Proteomics and Glycoproteomics in COVID-19 Biomarkers Identification
T2 - A Mini-review
AU - Zhong, Li
AU - Zhu, Lin
AU - Cai, Zong-Wei
N1 - Funding Information:
This study was funded by SZSTC (SGDX20190816230207535) and obtained a donation from Kwok Chung Bo Fun Charitable Fund, which commemorates the establishment of the Kwok Yat Wai Endowed Chair of Environmental and Biological Analysis. All authors of this article contributed separately as follows: Li Zhong draft the manuscript, Lin Zhu revised the manuscript, and Zong-Wei Cai supervised the whole study and provided financial supports.
Publisher Copyright:
© The Nonferrous Metals Society of China 2021
PY - 2021/12
Y1 - 2021/12
N2 - The first corona-pandemic, coronavirus disease 2019 (COVID-19) caused a huge health crisis and incalculable damage worldwide. Knowledge of how to cure the disease is urgently needed. Emerging immune escaping mutants of the virus suggested that it may be potentially persistent in human society as a regular health threat as the flu virus. Therefore, it is imperative to identify appropriate biomarkers to indicate pathological and physiological states, and more importantly, clinic outcomes. Proteins are the performers of life functions, and their abundance and modification status can directly reflect the immune status. Protein glycosylation serves a great impact in modulating protein function. The use of both unmodified and glycosylated proteins as biomarkers has also been proved feasible in the studies of SARS, Zika virus, influenza, etc. In recent years, mass spectrometry-based glycoproteomics, as well as proteomics approaches, advanced significantly due to the evolution of mass spectrometry. We focus on the current development of the mass spectrometry-based strategy for COVID-19 biomarkers’ investigation. Potential application of glycoproteomics approaches and challenges in biomarkers identification are also discussed.
AB - The first corona-pandemic, coronavirus disease 2019 (COVID-19) caused a huge health crisis and incalculable damage worldwide. Knowledge of how to cure the disease is urgently needed. Emerging immune escaping mutants of the virus suggested that it may be potentially persistent in human society as a regular health threat as the flu virus. Therefore, it is imperative to identify appropriate biomarkers to indicate pathological and physiological states, and more importantly, clinic outcomes. Proteins are the performers of life functions, and their abundance and modification status can directly reflect the immune status. Protein glycosylation serves a great impact in modulating protein function. The use of both unmodified and glycosylated proteins as biomarkers has also been proved feasible in the studies of SARS, Zika virus, influenza, etc. In recent years, mass spectrometry-based glycoproteomics, as well as proteomics approaches, advanced significantly due to the evolution of mass spectrometry. We focus on the current development of the mass spectrometry-based strategy for COVID-19 biomarkers’ investigation. Potential application of glycoproteomics approaches and challenges in biomarkers identification are also discussed.
KW - Biomarker
KW - COVID-19
KW - Glycoproteomics
KW - Proteomics
KW - SARS-CoV-2
UR - http://www.scopus.com/inward/record.url?scp=85114387831&partnerID=8YFLogxK
U2 - 10.1007/s41664-021-00197-6
DO - 10.1007/s41664-021-00197-6
M3 - Review article
AN - SCOPUS:85114387831
SN - 2096-241X
VL - 5
SP - 298
EP - 313
JO - Journal of Analysis and Testing
JF - Journal of Analysis and Testing
IS - 4
ER -
